RegCell raised $66 million to advance a Nobel Prize-linked immune tolerance platform, combining a fully subscribed $44 million Series A financing with a $22 million non-dilutive grant from Japan’s AMED. The funding supports development activities around the company’s immune tolerance approach, which is positioned for longer-term translational impact. For investors and development teams, the split of equity and non-dilutive government support matters: it can extend runway while reducing dilution risk. It also suggests confidence in the platform’s underlying biological rationale and translational feasibility. The AMED component may also influence collaboration pathways in Japan and in multi-region development plans where regulatory acceptance of mechanism and translational readouts is key.